Clinical trials: cyclosporine
Breast Cancer, Cancer
A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833
This is a dosage escalation study to estimate the maximum tolerated dose of drug resistance inhibitor PSC 833 given in combination with paclitaxel.
- Conditions
- Breast Cancer, Cancer, Carcinoma, Renal Cell, Lymphoma
- Trial name
- NCT00001383
- Testing
- PSC 833, paclitaxel
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Lung; Disease, Interstitial, With Fibrosis, Dermatomyositis
Basiliximab Treating Interstitial Pneumonia of CADM
This is a 52-week, randomized, open and routine treatment controlled study. This study will assess the safety and efficacy of basiliximab as an add-on treatment for interstitial pneumonia in clinical amyopathic dermatomyositis…
- Trial name
- NCT03192657
- Testing
- Basiliximab, Calcineurin Inhibitors, Steroids
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Aplastic Anemia
Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole
The clinical symptoms of non transfusion dependent non severe aplastic anemia (NSAA) are often lighter than that of severe aplastic anemia.
- Trial name
- NCT03218657
- Testing
- levamisole hydrochloride, Androgens, Cyclosporins
- Where
- China
- Volunteers
- 248 people
- Sponsor
- Shengyun Lin
Dry Eye Syndromes
Study of Cyclosporine in the Treatment of Dry Eye Syndrome (ST-603-005)
The purpose of this phase 3 study is to determine the safety and efficacy of cyclosporine in the treatment of dry eye syndrome.
- Trial name
- NCT00502073
- Testing
- cyclosporine
- Where
- United States
- Sponsor
- Sirion Therapeutics, Inc.
Aplastic Anemia
Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA
In a randomized, controlled clinical trial, the efficacy and safety of rodsipil combined with cyclosporine versus cyclosporine alone in the treatment of newly diagnosed non-transfusion-dependent NSAA were compared.
- Trial name
- NCT06424639
- Testing
- Luspatercept, cyclosporine
- Where
- China
- Sponsor
- Peking Union Medical College Hospital
Dermatitis, Atopic
Systemic Therapies for Pediatric Atopic Dermatitis
While many patients with atopic dermatitis (eczema) can be managed with topical creams and treatments for itch, some children have such severe, long-standing disease that they need treatment with oral medications that decrease…
- Trial name
- NCT01447381
- Where
- 3 sites in United States
- Volunteers
- 250 people
- Sponsor
- Rady Children's Hospital, San Diego
Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis
This is a prospective, multicenter cohort observational; study to compare treatment outcomes in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis, aiming to assess the utility of medical…
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction
- Trial name
- NCT03585946
- Testing
- Site specific standard of care comparison
- Volunteers
- healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Multiple Myeloma
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an…
- Trial name
- NCT00006184
- Testing
- Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
CNI Side Effects
Calcineurin Inhibitor Sparing After Kidney Transplantation
Reducing drug side effects is a key issue in transplantation. One class of drugs commonly used, calcineurin inhibitors (CNIs), is associated with negative side effects, namely, toxicity to the transplanted kidney.
- Trial name
- CNI-Sparing (NCT01062555)
- Testing
- Cyclosporine & Cellcept, Prograf & Cellcept, Low Dose CNI (Cyclosporine or FK) and Cellcept
- Where
- United States
- Volunteers
- 527 people
- Sponsor
- University of Minnesota
Tacrolimus-associated Abnormal Glucose Metabolism in Kidney and Liver Transplant Recipients
Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsion
New onset diabetes mellitus (NODM) post- transplantation decreases patient and graft survival. Some immunosuppressive agents are associated with a higher incidence of NODM.
- Trial name
- NCT00150085
- Testing
- cyclosporine micro-emulsion
- Volunteers
- 50 people
- Sponsor
- Novartis
GI Disturbance
Myfortic Conversion Trial in OLT Recipients With GI Intolerance
Liver transplant patients often require multimodal immunosuppressive therapy to minimize their risk for rejection. In our regimen, MMF (mycophenolate mofetil) is often added to lower the side effects of the calcineurin…
- Trial name
- NCT00619216
- Testing
- Mycophenolic Acid (Myfortic)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of North Carolina, Chapel Hill
Ulcerative Colitis Acute
Efficacy of Cyclosporine Rescue Therapy in Acute Ulcerative Colitis.
The efficacy and safety of Cyclosporine A as rescue therapy for acute severe ulcerative colitis in long-term follow-up.
- Trial name
- Cyclo (NCT05219656)
- Testing
- Cyclosporine A
- Volunteers
- 182 people
- Sponsor
- Tampere University Hospital
Leukemia
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
RATIONALE: Giving chemotherapy before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT01020734
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 2 sites in South Korea
- Volunteers
- 263 people
- Sponsor
- Asan Medical Center
Healthy Volunteers
Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites
This is a Phase 1, randomized, parallel-group, open-label study. Forty subjects will be enrolled and will be randomized into 1 of the 2 treatment groups, with 20 subjects in each treatment group(sex will be used as a stratifying…
- Trial name
- NCT04149678
- Testing
- Ozanimod, Cyclosporine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Celgene
Dry Eye Syndrome (DES)
Potential Role of Ocular Surface Microbiome in Dry Eye: Microbial Interactions and Symptom Alleviation
Study design and sample collection This study is randomized, double-blind, and prospective trial. The inclusion criteria were as follows: patients aged 19 years or older with symptoms of dry eye syndrome.
- Trial name
- NCT06936462
- Testing
- topical cyclosporine eyedrops and hyaluronic eyedrops
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Hallym University Kangnam Sacred Heart Hospital
Renal Transplantation
Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
The purpose of this study is to assess whether a calcineurin inhibitor (CNI)-free regimen with enteric-coated mycophenolate sodium (EC-MPS) and everolimus is as safe and well-tolerated as the standard regimen containing…
- Trial name
- NCT00154310
- Testing
- Everolimus, Cyclosporine, Enteric-coated mycophenolate sodium
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 300 people
- Sponsor
- Novartis
Chronic Hepatitis C Genotype-1 Relapse
Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients
This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reduction compared to SOC alone.
- Trial name
- NCT00983060
- Testing
- NIM811
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Myeloid Tumor
ATG/PTCy in Haplo-PBSCT Randomized Controlled,Multi-center
A novel regimen, which is composed of a low dose of ATG (5 mg/kg) and low-dose PTCy (one dose of PTCy, 50mg/kg) for GvHD prophylaxis in Haplo-PBSCT for patients with hematologic malignancies, was designed to decrease the risk of…
- Trial name
- ATG/PTCy (NCT03608059)
- Testing
- ATG/PTCy, standard ATG, standard PTCy
- Where
- 6 sites in China
- Volunteers
- 418 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Retinitis Pigmentosa
Autoimmunity in Retinitis Pigmentosa
Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.
- Trial name
- NCT00433277
- Testing
- twice-daily dosage with 0.5% cyclosporine-A eyedrops
- Where
- Hungary
- Sponsor
- Semmelweis University
End Stage Liver Disease, Hepatitis C
Study of Liver Transplant For End-Stage Liver Disease Caused By Chronic Hepatitis C Infection
The purpose of this study is to compare three treatment regimens in patients who have received a liver transplant for end-stage liver disease caused by Chronic Hepatitis C infection.
- Trial name
- NCT00163657
- Testing
- Daclizumub, Tacrolimus, Cyclosporine
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Baylor Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.